NCT02627443 - Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 16, 2017

Primary Completion Date

October 4, 2024

Study Completion Date

June 3, 2026

Conditions

Metastatic Fallopian Tube CarcinomaMetastatic Ovarian CarcinomaMetastatic Primary Peritoneal CarcinomaOvarian Endometrioid TumorOvarian High Grade Serous AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaStage IV Fallopian Tube Cancer AJCC v6 and v7Stage IV Ovarian Cancer AJCC v6 and v7Stage IV Primary Peritoneal Cancer AJCC v7

Interventions

DRUG

Berzosertib

Given IV

DRUG

Carboplatin

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (14)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

19107

Thomas Jefferson University Hospital, Philadelphia

22908

University of Virginia Cancer Center, Charlottesville

32610

University of Florida Health Science Center - Gainesville, Gainesville

40536

University of Kentucky/Markey Cancer Center, Lexington

48201

Wayne State University/Karmanos Cancer Institute, Detroit

48334

Weisberg Cancer Treatment Center, Farmington Hills

55905

Mayo Clinic in Rochester, Rochester

63110

Washington University School of Medicine, St Louis

80045

UCHealth University of Colorado Hospital, Aurora

85054

Mayo Clinic Hospital in Arizona, Phoenix

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH